

Accelerating Today's Novel Biology Into Tomorrow's New Medicines

Xcellomics™ is a collaboration between Exscientia and the University of Oxford Target Discovery Institute (TDI) to help accelerate early drug discovery research. Academic researchers are invited to submit cellular functional assays for consideration to potentially be developed into novel screens for target discovery. Participants retain co-ownership of IP, including the right to publish work and potentially receive milestone payments as a result of successful project execution.

The Application Process



STEP 1

Call For Proposals and Applications

Submit a short description and key details of your disease-relevant assays, which have the potential to be developed into medium- to high-throughput screens.



STEP 2

Review and Selection

Your application will be reviewed and scored based on disease-relevance, novelty and feasibility for screening.



STEP 3

Participant Engagement

Applications are reviewed quarterly, and you will be notified via email as soon as an update is available. If successful, you will be invited to formally join Xcellomics.



STEP 4

Assay Validation

Developed screening assays are evaluated for robustness, reproducibility and variability.



STEP 5

Assay Development

Assays are transferred to the TDI for development into screening and automation-compatible formats.



STEP 6

Screen Execution

A 50,000 diversity small molecule library or a genome-wide CRISPR library will be tested in the developed screen; potential trigger for milestone payment.



STEP 7

Data Analysis

Screening output data undergoes bioinformatics-driven analysis, with hits identified and preliminary target deconvolution performed. Hit validation and follow up studies can also take place.

